MA47719A - Esketamine pour le traitement de la dépression - Google Patents
Esketamine pour le traitement de la dépressionInfo
- Publication number
- MA47719A MA47719A MA047719A MA47719A MA47719A MA 47719 A MA47719 A MA 47719A MA 047719 A MA047719 A MA 047719A MA 47719 A MA47719 A MA 47719A MA 47719 A MA47719 A MA 47719A
- Authority
- MA
- Morocco
- Prior art keywords
- esketamine
- depression
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609504P | 2017-12-22 | 2017-12-22 | |
| US201862663206P | 2018-04-26 | 2018-04-26 | |
| US201862663219P | 2018-04-26 | 2018-04-26 | |
| US201862667406P | 2018-05-04 | 2018-05-04 | |
| US201862675846P | 2018-05-24 | 2018-05-24 | |
| US201862755905P | 2018-11-05 | 2018-11-05 | |
| EP18215651.3A EP3501542B1 (fr) | 2017-12-22 | 2018-12-21 | Esketamine pour le traitement de la dépression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA47719A true MA47719A (fr) | 2020-01-15 |
| MA47719B1 MA47719B1 (fr) | 2026-03-31 |
Family
ID=65003585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA47719A MA47719B1 (fr) | 2017-12-22 | 2018-12-21 | Esketamine pour le traitement de la dépression |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11707440B2 (fr) |
| EP (2) | EP3501542B1 (fr) |
| JP (3) | JP7807870B2 (fr) |
| KR (3) | KR102966746B1 (fr) |
| CN (2) | CN117531017A (fr) |
| AU (2) | AU2018282466A1 (fr) |
| BR (1) | BR112020012473A2 (fr) |
| CA (1) | CA3086478A1 (fr) |
| DK (1) | DK3501542T3 (fr) |
| ES (1) | ES3068171T3 (fr) |
| FI (1) | FI3501542T3 (fr) |
| HR (1) | HRP20260519T1 (fr) |
| IL (2) | IL319020A (fr) |
| JO (1) | JOP20200156A1 (fr) |
| LT (1) | LT3501542T (fr) |
| MA (1) | MA47719B1 (fr) |
| MX (2) | MX2020006650A (fr) |
| PH (1) | PH12020500555A1 (fr) |
| PL (1) | PL3501542T3 (fr) |
| PT (1) | PT3501542T (fr) |
| RS (1) | RS68008B1 (fr) |
| SG (1) | SG11202005896WA (fr) |
| SI (1) | SI3501542T1 (fr) |
| SM (1) | SMT202600184T1 (fr) |
| TW (2) | TWI843711B (fr) |
| WO (1) | WO2019126108A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140274981A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| EP3193853A1 (fr) | 2014-09-15 | 2017-07-26 | Janssen Pharmaceutica NV | Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| SG11202005896WA (en) | 2017-12-22 | 2020-07-29 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| DK3505157T3 (da) | 2017-12-29 | 2022-02-28 | Celon Pharma Sa | Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression |
| CA3103440A1 (fr) | 2018-06-27 | 2020-01-02 | Clexio Biosciences Ltd. | Procede de traitement d'un trouble depressif majeur |
| WO2020070706A1 (fr) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Régime posologique d'eskétamine pour le traitement d'un trouble dépressif majeur |
| WO2020075134A1 (fr) | 2018-10-11 | 2020-04-16 | Clexio Biosciences Ltd. | Eskétamine pour une utilisation dans le traitement d'un trouble dépressif majeur |
| EP3934632A4 (fr) * | 2019-03-05 | 2022-11-23 | Janssen Pharmaceuticals, Inc. | Eskétamine pour le traitement de la dépression |
| EP4364812A3 (fr) * | 2019-05-31 | 2024-09-04 | Afyx Development A/S | Administration intranasale de kétamine à des patients atteints d'algie vasculaire de la face |
| EP3923920A4 (fr) * | 2019-08-05 | 2022-11-23 | The Ketamine Research Foundation | Kétamine pour le traitement de symptômes et de troubles post-partum |
| EP4021432A4 (fr) | 2019-08-28 | 2023-08-16 | Janssen Pharmaceuticals, Inc. | Eskétamine pour le traitement de patients présentant un trouble dépressif majeur, notamment la suicidalité |
| CN115135363A (zh) * | 2019-09-13 | 2022-09-30 | 杨森制药公司 | 艾司氯胺酮的鼻内施用 |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| WO2021137147A1 (fr) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Régime posologique à base d'eskétamine pour le traitement d'un trouble dépressif majeur |
| US12685714B2 (en) | 2020-08-18 | 2026-07-21 | Oakwood Laboratories, Llc | Microsphere formulations comprising ketamine and methods for making and using the same |
| CN115942935B (zh) * | 2020-08-18 | 2025-09-05 | 奥克伍德实验室有限责任公司 | 包括氯胺酮的微球制剂及其制备和使用方法 |
| CA3199076A1 (fr) * | 2020-10-22 | 2022-04-28 | Tonix Pharmaceuticals Holding Corp. | Procedes de respect de randomisation pour evaluer la signification d'interventions sur des resultats dans des troubles |
| EP4494634A4 (fr) * | 2022-04-26 | 2025-07-23 | Yichang Humanwell Pharmaceutical Co Ltd | Préparation liquide d'eskétamine et son utilisation |
| EP4687860A1 (fr) * | 2023-03-24 | 2026-02-11 | Janssen Pharmaceutica NV | Eskétamine destinée à être utilisée dans le traitement de la dépression |
| JP2026522628A (ja) * | 2023-06-21 | 2026-07-08 | クリストコット リミティド ライアビリティ カンパニー | 痔疾患症状インパクト測定法の開発及び検証 |
| WO2025106879A1 (fr) * | 2023-11-15 | 2025-05-22 | Gilgamesh Pharmaceuticals, Inc. | Méthodes de traitement de troubles psychiatriques ou de la douleur à l'aide de (r)-2-(4-fluorophényl)-2-(méthylamino) cyclohexan-1-one ou de sels pharmaceutiquement acceptables de ceux-ci |
| AU2025213102A1 (en) * | 2024-01-26 | 2026-07-16 | Inesket Llc | Ketamine nasal spray formulation and methods of use |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10025A (en) | 1853-09-20 | Improvement in turbines | ||
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| DK0814790T3 (da) | 1995-02-24 | 2003-11-10 | Stuart L Weg | Indgivelse af ketamin med henblik på afgiftning |
| WO1997007750A1 (fr) | 1995-08-30 | 1997-03-06 | Weg Stuart L | Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments |
| FR2739294B1 (fr) | 1995-09-29 | 1998-01-16 | Lhd Lab Hygiene Dietetique | Embout nasal de securite |
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| DE19723133A1 (de) | 1997-06-03 | 1998-12-10 | Caideil M P Teoranta Tourmakea | Austragvorrichtung für Medien |
| FR2764807B1 (fr) | 1997-06-18 | 1999-08-20 | Valois Sa | Dispositif de distribution nasale d'un produit fluide ou pulverulent |
| CA2338457C (fr) | 1998-07-24 | 2009-11-17 | Seo Hong Yoo | Preparation de dosages de solution claire aqueuse avec des acides biliaires |
| US6599883B1 (en) | 1998-10-30 | 2003-07-29 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of xylitol |
| US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| US6017961A (en) | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
| EP1103256A1 (fr) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique |
| US6572849B2 (en) | 2000-09-20 | 2003-06-03 | Lee Shahinian, Jr. | Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications |
| US6881731B1 (en) | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
| EP1551393A4 (fr) | 2002-07-30 | 2010-06-16 | Peter Migaly | Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| JP2006510618A (ja) | 2002-11-18 | 2006-03-30 | ヤウポン セラピューティクス，インコーポレーテッド | ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用 |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US8082173B2 (en) | 2003-05-22 | 2011-12-20 | Cecil Kost | Drug sample fulfillment architecture |
| US20040265364A1 (en) | 2003-06-25 | 2004-12-30 | Binnur Ozturk | Neuropathy cream |
| US20050095277A1 (en) | 2003-06-25 | 2005-05-05 | Binnur Ozturk | Neuropathy cream |
| US20060223788A1 (en) | 2005-03-29 | 2006-10-05 | Cathcart Clifton H | Analgesic composition for topical use |
| EP2526987A3 (fr) | 2005-06-01 | 2013-04-24 | SHL Group AB | Dispositif pour administrer un médicament |
| US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
| JP2009530385A (ja) | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| US20070256688A1 (en) | 2006-04-21 | 2007-11-08 | Aradigm Corporation | Mechanical single dose intrapulmonary drug delivery devices |
| EP2029136A4 (fr) | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | Traitement pour troubles dépressifs |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| WO2008151179A2 (fr) | 2007-06-04 | 2008-12-11 | Auspex Pharmaceuticals, Inc. | Phénéthylamines substituées |
| WO2009131794A1 (fr) | 2008-03-27 | 2009-10-29 | University Of Kentucky Research Foundation | Combinaisons de co-médicament opioïdekétamine et norkétamine dans la gestion de la douleur |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| AU2011267474B2 (en) | 2010-06-15 | 2016-05-26 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| WO2013003669A2 (fr) | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, méthodes d'utilisation et méthodes de traitement |
| JP6296985B2 (ja) | 2011-10-14 | 2018-03-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用 |
| CN104053785A (zh) | 2011-11-14 | 2014-09-17 | 综合医院公司 | 为患有抑郁症的受试者选择治疗方案的测定法和方法 |
| US20130209585A1 (en) | 2012-02-13 | 2013-08-15 | Stanley Kim | Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy |
| WO2013138322A1 (fr) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Eskétamine dans le traitement de la dépression réfractaire ou résistante aux traitements |
| AU2016203771A1 (en) | 2012-03-13 | 2016-06-23 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| JP2015512418A (ja) | 2012-03-30 | 2015-04-27 | ザ ジェネラル ホスピタル コーポレイション | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
| US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| MX2015002378A (es) | 2012-08-23 | 2015-09-25 | Stuart L Weg | Composicion ansiolitica, formulacion y metodo de uso. |
| FR2994844B1 (fr) | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | Formulation gelifiante a base de ketamine |
| NZ619257A (en) | 2012-10-08 | 2015-07-31 | Auckland Uniservices Ltd | Ketamine derivatives |
| ES2484068B1 (es) | 2013-02-08 | 2015-04-16 | Ana MÍNGUEZ MARTÍ | Una composición farmacéutica que contiene ketamina y amitriptilina |
| KR20220044380A (ko) | 2013-04-12 | 2022-04-07 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 외상후 스트레스 장애의 치료 방법 |
| US9913803B2 (en) | 2013-08-26 | 2018-03-13 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| DK3043785T3 (da) | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
| CN103705909A (zh) | 2013-12-16 | 2014-04-09 | 陈镜伊 | 一种无痛人流用药 |
| WO2015101693A1 (fr) | 2013-12-31 | 2015-07-09 | Servicio Andaluz De Salud | Compositions et préparations combinées pour le traitement des douleurs oropharyngées |
| CA2936809A1 (fr) | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprenant de la ketamine pour le traitement d'un trouble du spectre de l'autisme |
| EP3272338B1 (fr) | 2014-04-17 | 2020-09-09 | Develco Pharma Schweiz AG | Forme posologique orale de kétamine |
| PE20211759A1 (es) | 2014-05-04 | 2021-09-07 | Firmenich & Cie | Formulacion edulcorante con naringenina |
| FR3023188B1 (fr) | 2014-07-04 | 2016-08-19 | Aptar France Sas | Dispositif de distribution de produit fluide. |
| US10098854B2 (en) * | 2014-08-13 | 2018-10-16 | Janssen Pharmaceutica Nv | Method for the treatment of depression |
| EP3193853A1 (fr) * | 2014-09-15 | 2017-07-26 | Janssen Pharmaceutica NV | Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression |
| WO2016109427A1 (fr) | 2014-12-31 | 2016-07-07 | Icahn School Of Medicine At Mount Sinai | Procédé de maintien de l'effet antidépresseur de la kétamine avec du lithium |
| CN104798728A (zh) | 2015-05-08 | 2015-07-29 | 南京中医药大学 | 产后抑郁动物模型的建立方法及其应用 |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| US20180296478A1 (en) | 2016-02-12 | 2018-10-18 | Synergistic Therapeutics, Llc | Sublingual antidepressant and antianxiety tablet |
| US20180042936A1 (en) | 2016-03-18 | 2018-02-15 | Genomind, Inc. | Maintenance therapy using tianeptine |
| SG11202005896WA (en) | 2017-12-22 | 2020-07-29 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
-
2018
- 2018-12-18 SG SG11202005896WA patent/SG11202005896WA/en unknown
- 2018-12-18 US US16/956,403 patent/US11707440B2/en active Active
- 2018-12-18 KR KR1020207021196A patent/KR102966746B1/ko active Active
- 2018-12-18 KR KR1020247000937A patent/KR20240011237A/ko not_active Ceased
- 2018-12-18 WO PCT/US2018/066143 patent/WO2019126108A1/fr not_active Ceased
- 2018-12-18 MX MX2020006650A patent/MX2020006650A/es unknown
- 2018-12-18 CA CA3086478A patent/CA3086478A1/fr active Pending
- 2018-12-18 CN CN202311355796.8A patent/CN117531017A/zh active Pending
- 2018-12-18 IL IL319020A patent/IL319020A/en unknown
- 2018-12-18 BR BR112020012473-7A patent/BR112020012473A2/pt unknown
- 2018-12-18 KR KR1020267015292A patent/KR20260085455A/ko active Pending
- 2018-12-18 JO JOP/2020/0156A patent/JOP20200156A1/ar unknown
- 2018-12-18 CN CN201880090058.6A patent/CN112423789A/zh active Pending
- 2018-12-18 IL IL275482A patent/IL275482B1/en unknown
- 2018-12-18 JP JP2020534520A patent/JP7807870B2/ja active Active
- 2018-12-21 FI FIEP18215651.3T patent/FI3501542T3/fi active
- 2018-12-21 RS RS20260479A patent/RS68008B1/sr unknown
- 2018-12-21 ES ES18215651T patent/ES3068171T3/es active Active
- 2018-12-21 HR HRP20260519TT patent/HRP20260519T1/hr unknown
- 2018-12-21 PT PT182156513T patent/PT3501542T/pt unknown
- 2018-12-21 DK DK18215651.3T patent/DK3501542T3/da active
- 2018-12-21 MA MA47719A patent/MA47719B1/fr unknown
- 2018-12-21 SM SM20260184T patent/SMT202600184T1/it unknown
- 2018-12-21 EP EP18215651.3A patent/EP3501542B1/fr active Active
- 2018-12-21 SI SI201831316T patent/SI3501542T1/sl unknown
- 2018-12-21 LT LTEP18215651.3T patent/LT3501542T/lt unknown
- 2018-12-21 TW TW107146335A patent/TWI843711B/zh active
- 2018-12-21 PL PL18215651.3T patent/PL3501542T3/pl unknown
- 2018-12-21 TW TW112130258A patent/TW202415363A/zh unknown
- 2018-12-21 AU AU2018282466A patent/AU2018282466A1/en not_active Abandoned
- 2018-12-21 EP EP26154336.7A patent/EP4755453A3/fr active Pending
-
2020
- 2020-06-18 PH PH12020500555A patent/PH12020500555A1/en unknown
- 2020-07-13 MX MX2023012450A patent/MX2023012450A/es unknown
-
2023
- 2023-07-05 US US18/347,393 patent/US20240000728A1/en not_active Abandoned
- 2023-10-06 JP JP2023174444A patent/JP2024001204A/ja not_active Withdrawn
-
2024
- 2024-10-17 AU AU2024227438A patent/AU2024227438B2/en active Active
- 2024-12-20 US US18/991,118 patent/US20250332121A1/en active Pending
-
2025
- 2025-10-15 JP JP2025173453A patent/JP2026027257A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448987A4 (fr) | Compositions pour le traitement de maladies | |
| EP3504187A4 (fr) | Utilisation de la pridopidine pour le traitement du déclin fonctionnel | |
| EP3370703A4 (fr) | Combinaison de gemcabène pour le traitement de maladies cardiovasculaires | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| IL275482A (en) | Asketamine for the treatment of depression | |
| EP3503890A4 (fr) | Utilisation de la pridopidine pour le traitement des dystonies | |
| EP3494142A4 (fr) | Anticorps anti-siglec-7 pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| EP3362065A4 (fr) | Polythérapie pour le traitement de malignités | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| EP3630196A4 (fr) | Polythérapies pour le traitement de cancers | |
| EP3288592A4 (fr) | Utilisation de cannabidiol pour le traitement de spasmes infantiles | |
| EP3335041A4 (fr) | Biomarqueurs pour le traitement de la pelade | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| EP3328374A4 (fr) | Antagonistes de la glutamine pour le traitement de déficits cognitifs | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3383497A4 (fr) | Nouveaux anticorps pour le traitement de cancers | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3512506A4 (fr) | Utilisation de la pridopidine pour le traitement du syndrome de rett | |
| EP3766497A4 (fr) | Médicament pour le traitement de la toux |